• +1-646-491-9876
    • +91-20-67278686

    Search

    Human Papillomavirus Protein E6-Pipeline Review H1 2017

    Human Papillomavirus Protein E6-Pipeline Review H1 2017

    • Report Code ID: RW0001834355
    • Category Pharmaceuticals
    • No. of Pages 73
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2017

    Summary

    Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It is a 151 amino-acid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.

    Human Papillomavirus Protein E6 (E6) pipeline Target constitutes close to 24 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 9 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Cervical Intraepithelial Neoplasia (CIN) , Head And Neck Cancer, Human Papillomavirus Infections and Lung Cancer.

    The latest report Human Papillomavirus Protein E6 (E6) - Pipeline Review, H1 2017, outlays comprehensive information on the Human Papillomavirus Protein E6 (E6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
    - The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Human Papillomavirus Protein E6 (E6) - Overview
    Human Papillomavirus Protein E6 (E6) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
    Abion Inc
    BioNTech AG
    Cancer Research Technology Ltd
    Etubics Corp
    Genexine Inc
    Hookipa Biotech AG
    Inovio Pharmaceuticals Inc
    MedImmune LLC
    Rottapharm Biotech Srl
    Selecta Biosciences Inc
    Tomegavax Inc
    Transgene SA
    Human Papillomavirus Protein E6 (E6) - Drug Profiles
    ABN-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ETBX-041 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GX-188E - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HB-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    human papillomavirus [serotype 16] vaccine 1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    human papillomavirus [serotypes 16] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    human papillomavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    INO-3106 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-0457 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PVX-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SEL-701 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TA-CIN - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-4001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tricurin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VGX-3100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vvax-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Human Papillomavirus Protein E6 (E6) - Dormant Products
    Human Papillomavirus Protein E6 (E6) - Discontinued Products
    Human Papillomavirus Protein E6 (E6) - Product Development Milestones
    Featured News & Press Releases
    May 10, 2017: Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
    Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
    Mar 06, 2017: Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
    Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
    Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
    Oct 17, 2016: Hookipa Secures EUR 4.16 Million Additional Grant Support from the Austrian Research Promotion Agency (FFG) to Develop Arenavirus Vector-Based Cancer Immunotherapies
    Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
    Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
    Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress
    Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan
    Nov 05, 2015: Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
    Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
    Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial
    Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe
    Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Abion Inc, H1 2017
    Pipeline by BioNTech AG, H1 2017
    Pipeline by Cancer Research Technology Ltd, H1 2017
    Pipeline by Etubics Corp, H1 2017
    Pipeline by Genexine Inc, H1 2017
    Pipeline by Hookipa Biotech AG, H1 2017
    Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Pipeline by MedImmune LLC, H1 2017
    Pipeline by Rottapharm Biotech Srl, H1 2017
    Pipeline by Selecta Biosciences Inc, H1 2017
    Pipeline by Tomegavax Inc, H1 2017
    Pipeline by Transgene SA, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Abion Inc
    BioNTech AG
    Cancer Research Technology Ltd
    Etubics Corp
    Genexine Inc
    Hookipa Biotech AG
    Inovio Pharmaceuticals Inc
    MedImmune LLC
    Rottapharm Biotech Srl
    Selecta Biosciences Inc
    Tomegavax Inc
    Transgene SA

    Request for Sample

    Report Url https://www.reportsweb.com//human-papillomavirus-protein-e6-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//human-papillomavirus-protein-e6-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//human-papillomavirus-protein-e6-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments